AAD
Author: Willhemenia Loremipsum Special session: Lorem ipsum dolor sit amet Category: Lorem ipsum View all results

Please login or create an account. If you do not have access to this content, you will be shown a 30 second preview and licensing options.

  • Presentation

Melasma: Newer Medical Management Strategies for 2025

Description

The presentation discusses the evolving management strategies for melasma, emphasizing the need for a multi-faceted treatment approach due to its complex etiology, which may include factors like sun exposure, hormonal influences, and pollution. Current first-line treatments comprise topical depigmenting agents like hydroquinone, sunscreen use, and cosmetic camouflage. Newer therapies are emerging, including anti-histamines, various oral agents, and novel topical treatments combining anti-estrogen and vascular growth factors. The emphasis on incorporating sunscreen as an essential part of treatment is reiterated, particularly those that protect against visible light. Other innovative ideas include addressing the skin's microbiome and utilizing new ingredients, such as malicisin and metformin, for their potential benefits in managing melasma. An important shift noted is the recognition of melasma as a photo-aging disorder, prompting consideration of genetics in its treatment. New methods, including imaging technologies to track treatment progress, along with a collaborative approach combining topical, oral, and procedural therapies, are advised. The speaker concludes by underscoring melasma as a chronic condition requiring ongoing management and increased awareness of newer therapies among healthcare providers.

View more

Conclusions

  • Melasma is a chronic and therapeutically challenging condition that requires constant management.
  • A multi-modal approach is essential for effective treatment of melasma, including topical agents, oral therapies, and procedures.
  • New treatments for melasma are focusing on understanding its multifactorial etiopathogenesis, addressing factors like sun exposure, pollution, and hormones.
  • Photoprotection is critical in managing melasma, with emphasis on using effective sunscreens regularly.
  • There is growing evidence supporting the use of novel topical agents and systemic medications such as tranexamic acid for melasma management.
  • Combination therapies show promise, including the use of exosomes and new formulations targeting the microbiome and genetic factors.
  • Emerging treatments like thiamidol and isobionic-amide demonstrate significant efficacy in treating melasma.
  • Recognition of the psychological impact of melasma on patients underscores the need for comprehensive care.
  • Awareness and education regarding newer therapies are crucial for healthcare providers to enhance treatment options for melasma.
  • Mahakan VK. J Cosmet Dermatol. 2022;21:3707-3728
  • Desai SM. J Am Acad Dermatol. 2024; 90: 269-79
  • Passeron T. Melasma, a photoaging disorder. Pigment Cell & Melanoma Research. 2017; 31(4):461-5
  • Moon HR, Jo SY, Kim HT, Lee WJ, Won CH, Lee MW, Choi JH, Chang SE. Loratadine, an H1Antihistamine, Inhibits Melanogenesis in Human Melanocytes. Biomed Res Int. 2019 Mar 17;2019:5971546
  • Craig Arrowitz, Andrea M. Schoelermann, Tobias Mann, Lily I. Jiang, Teresa Weber, Ludger Kolbe. Effective Tyrosinase Inhibition by Thiamidol Results in Significant Improvement of Mild to Moderate Melasma. Journal of Investigative Dermatology, Volume 139, Issue 8, 2019,Pg 1691-1698
  • M Sachdev, M Ramnane, A Alexis, D Kerob, N Kerrouche, T Passeron. Randomized Controlled Investigator Blinded Comparative Study of the Efficacy and Tolerability of Test Product versus Cysteamine 5% in the Treatment of Facial Melasma over 4 Months. Late breaking oral communication. EADV 2024
  • Benoit Muller1 | Frederic Flament1 | Hussein Jouni2 | Peggy Sextius2 | David Amar5 | Caroline Delaunay5 | Nina G. Jablonski6 | Thierry Passeron7,8. A Bayesian network meta-analysis of 14 molecules inhibiting UV daylight-induced pigmentation. DOI: 10.1111/pcmr.13168
  • Wang T, Gao H, Wang D, Zhang C, Hu K, Zhang H, Lin J, Chen X. Stem cell-derived exosomes in the treatment of melasma and its percutaneous penetration. Lasers Surg Med. 2023 Feb;55(2):178-189.
  • Liu C, He D, Yu A, Deng Y, Wang L, Song Z. Correlation analysis between gut microbiota characteristics and melasma. Front Microbiol. 2022 Nov 17;13:1051653m.
  • Piyavatin P, Chaichalotornkul S, Nararatwanchai T, Bumrungpert A, Saiwichai T. Synbiotics supplement is effective for Melasma improvement. J Cosmet Dermatol. 2021 Sep;20(9):2841-2850.
  • Grimes, Pearl E. et al. A novel proof-of-concept study assessing the lightening effects and safety of malassezin for treatment of facial hyperpigmentation. Journal of the American Academy of Dermatology, Aug 2022 Volume 87, Issue 2, 456-458.